BioRestorative Therapies closes $5 million public offering By Investing.com

robot
Abstract generation in progress

BioRestorative Therapies (NASDAQ:BRTX) has completed a $5 million public offering, issuing shares and warrants at $0.35 per share. Despite the new capital, the stock has recently plummeted over 72%, although InvestingPro data suggests it is undervalued. The proceeds will fund clinical trials for its BRTX-100 cell therapy, pre-clinical research for its ThermoStem Program, and development of its biocosmeceuticals platform.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)